The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities

<b>Objective:</b> This study estimates the cost-effectiveness of vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) among infants in Beijing, Shanghai, Shenzhen, Chengdu, Karamay, Qingdao, and Suzhou. <b>Methods:</b> A previously published cost-effectivenes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yan Li, Huaqing Wang, Wesley Furnback, Bruce C. M. Wang, Shuiqing Zhu, Peng Dong
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cost-effectiveness pneumococcal conjugate vaccine PCV 13 China Medicine R
Acceso en línea:	https://doaj.org/article/5ee78075201c4c44bc2aa604eb35ca84
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5ee78075201c4c44bc2aa604eb35ca84
record_format	dspace
spelling	oai:doaj.org-article:5ee78075201c4c44bc2aa604eb35ca842021-11-25T19:11:41ZThe Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities10.3390/vaccines91113682076-393Xhttps://doaj.org/article/5ee78075201c4c44bc2aa604eb35ca842021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1368https://doaj.org/toc/2076-393X<b>Objective:</b> This study estimates the cost-effectiveness of vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) among infants in Beijing, Shanghai, Shenzhen, Chengdu, Karamay, Qingdao, and Suzhou. <b>Methods:</b> A previously published cost-effectiveness model comparing vaccination with PCV13 to no vaccination was localized to the included Chinese cities. A systematic literature review was undertaken to identify age-specific incidence rates for pneumococcal bacteremia, pneumococcal meningitis, pneumonia, and otitis media (AOM). Age-specific direct medical costs of treating the included pneumococcal diseases were taken from the Chinese Health Insurance Association database. The base case analysis evaluated vaccine efficacy using direct effect and indirect effects (DE+ IDE). A subsequent scenario analysis evaluated the model outcomes if only DE was considered. A vaccination rate of 70% was used. The model reported outcomes over a one-year period after it was assumed the vaccine effects had reached a steady state (5–7 years after vaccine introduction) to include the direct and indirect effects of vaccination. Health outcomes were discounted at 5% during the steady-state period. <b>Results:</b> Vaccination with PCV13 was cost-effective in the base case analysis for all included cities with the incremental cost-effectiveness ratio (ICER) ranging from 1145 CNY(Shenzhen) to 15,422 CNY (Qingdao) per quality-adjusted life-year (QALY) gained. PCV13 was the dominant strategy in Shanghai with lower incremental costs and higher incremental QALYs. PCV13 remained cost-effective in the DE-only analysis with all ICERs falling below a cost-effectiveness threshold of three times GDP per capita in each city. <b>Conclusions:</b> Vaccination with PCV13 was a cost-effective strategy in the analyzed cities for both the DE-only and DE + IDE analyses. PCV13 became very cost-effective when a vaccination rate was reached where IDE is observed.Yan LiHuaqing WangWesley FurnbackBruce C. M. WangShuiqing ZhuPeng DongMDPI AGarticlecost-effectivenesspneumococcal conjugate vaccinePCV 13ChinaMedicineRENVaccines, Vol 9, Iss 1368, p 1368 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cost-effectiveness pneumococcal conjugate vaccine PCV 13 China Medicine R
spellingShingle	cost-effectiveness pneumococcal conjugate vaccine PCV 13 China Medicine R Yan Li Huaqing Wang Wesley Furnback Bruce C. M. Wang Shuiqing Zhu Peng Dong The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
description	<b>Objective:</b> This study estimates the cost-effectiveness of vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) among infants in Beijing, Shanghai, Shenzhen, Chengdu, Karamay, Qingdao, and Suzhou. <b>Methods:</b> A previously published cost-effectiveness model comparing vaccination with PCV13 to no vaccination was localized to the included Chinese cities. A systematic literature review was undertaken to identify age-specific incidence rates for pneumococcal bacteremia, pneumococcal meningitis, pneumonia, and otitis media (AOM). Age-specific direct medical costs of treating the included pneumococcal diseases were taken from the Chinese Health Insurance Association database. The base case analysis evaluated vaccine efficacy using direct effect and indirect effects (DE+ IDE). A subsequent scenario analysis evaluated the model outcomes if only DE was considered. A vaccination rate of 70% was used. The model reported outcomes over a one-year period after it was assumed the vaccine effects had reached a steady state (5–7 years after vaccine introduction) to include the direct and indirect effects of vaccination. Health outcomes were discounted at 5% during the steady-state period. <b>Results:</b> Vaccination with PCV13 was cost-effective in the base case analysis for all included cities with the incremental cost-effectiveness ratio (ICER) ranging from 1145 CNY(Shenzhen) to 15,422 CNY (Qingdao) per quality-adjusted life-year (QALY) gained. PCV13 was the dominant strategy in Shanghai with lower incremental costs and higher incremental QALYs. PCV13 remained cost-effective in the DE-only analysis with all ICERs falling below a cost-effectiveness threshold of three times GDP per capita in each city. <b>Conclusions:</b> Vaccination with PCV13 was a cost-effective strategy in the analyzed cities for both the DE-only and DE + IDE analyses. PCV13 became very cost-effective when a vaccination rate was reached where IDE is observed.
format	article
author	Yan Li Huaqing Wang Wesley Furnback Bruce C. M. Wang Shuiqing Zhu Peng Dong
author_facet	Yan Li Huaqing Wang Wesley Furnback Bruce C. M. Wang Shuiqing Zhu Peng Dong
author_sort	Yan Li
title	The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
title_short	The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
title_full	The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
title_fullStr	The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
title_full_unstemmed	The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
title_sort	cost-effectiveness of 13-valent pneumococcal conjugate vaccine in seven chinese cities
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/5ee78075201c4c44bc2aa604eb35ca84
work_keys_str_mv	AT yanli thecosteffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT huaqingwang thecosteffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT wesleyfurnback thecosteffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT brucecmwang thecosteffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT shuiqingzhu thecosteffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT pengdong thecosteffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT yanli costeffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT huaqingwang costeffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT wesleyfurnback costeffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT brucecmwang costeffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT shuiqingzhu costeffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities AT pengdong costeffectivenessof13valentpneumococcalconjugatevaccineinsevenchinesecities
_version_	1718410158390902784

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities

Ejemplares similares